एर्लोटिनिब और आइबुप्रोफेन और फैमोटिडीन का इंटरैक्शन

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ].

Drugs the Increase Gastric pH Co-administration of erlotinib with proton pump inhibitors (e.g., omeprazole) and H-2 receptor antagonists (e.g., ranitidine) decreased erlotinib exposure [see Clinical Pharmacology (12.3) ].

For H-2 receptor antagonists and antacids, modify the dosing schedule [see Dosage and Administration (2.4) ].

For H-2 receptor antagonists, take erlotinib 10 hours after H-2 receptor antagonist dosing.

For administration instructions of other drugs whose absorption is dependent on gastric pH, refer to their prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine).